

340B IN ACTION

Winneshiek Medical Center



The 340B prescription drug program is a vital lifeline for safety-net providers, supporting critical health services in our communities. The program is tailored to reach only hospitals that provide a high level of services to low-income individuals or that serve isolated rural communities. Savings from the 340B program help hospitals meet the healthcare needs of underserved patients across the country.

340B by the Numbers:

\$1.5M

Our approximate annual 340B cost savings and benefit

\$3.4M

Our approximate uncompensated care provided last year which includes State and Federal programs

\$1.4M

COVID-19 Preparedness through June 2020

\$750K

Spent for patient safety

The 340B Impact in Our Community:

Winneshiek Medical Center has earned The Joint Commission's Gold Seal of Approval® for accreditation by demonstrating compliance with The Joint Commission's national standards for health care quality and safety in hospitals. The accreditation award recognizes Winneshiek Medical Center's dedication to continuous compliance with The Joint Commission's state-of-the-art standards. Accreditation covers physician services by Mayo Clinic Health System, including the clinic in Decorah and satellite clinics in Ossian and Mabel, Home Health, Hospice and Durable Medical Equipment (DME).

Winneshiek Medical Center is a safety-net provider for the area, serving the residents of Winneshiek County and surrounding counties of North East Iowa.

Providing health and wellness services to the communities we serve.

Serve uninsured or under-insured patients who require outpatient infusion services who receive critical medications regardless of their ability to pay.

Without Winneshiek Medical Center, our patients would have to drive to the next closest institution to receive services otherwise not available in our community including infusion services to treat oncology.

With the completion of the pharmacy renovation Winneshiek Medical Center is able to meet the new standards for safe handling of hazardous drugs. These new standards promote patient safety, work safety, and environmental protection.